FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 284 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR EMA Recommends Granting a Marketing Authorisation for a Biosimilar Bevacizumab, Onbevzi November 23, 2020 Three Brothers Under The Age Of 6 Are All Fighting The... February 7, 2020 AI and remote monitoring are shaping a new patient journey in... August 26, 2025 Can cancer cells communicate? February 28, 2023 Load more HOT NEWS FDA Approves Lutetium Lu 177 Dotatate for Paediatric Patients 12 Years... Why I Choose to Live With Gratitude During Metastatic Breast Cancer How Fatty Liver Disease Helps Cancer Thrive in the Liver Advancing Cancer Research as a Married Couple: “Your Stories” Podcast
